Amendments to the Specification:

Please replace the paragraph beginning at page 1, line 24 with the following amended paragraph:

With advances in monoclonal antibody technology and recombinant DNA technology, large-scale production of pure immunoglobulins has become possible in recent years. Furthermore, gene recombination techniques have enabled production of chimeric antibodies and humanized antibodies. Chimeric antibodies are antibodies having a structure in which the variable regions have been replaced with variable regions derived from a different species. For example, "chimeric antibodies" comprising variable regions of non-human antibodies and the constant regions of human antibodies (Non-Patent Document 1/ Proc. Natl. Acad. Sci. U.S.A., (1984) 81:6851) are known. Also known are humanized antibodies in which the complementarity determining regions (CDR) of other animal species are transferred into human immunoglobulins (Non-Patent Document 2/ Nature (1986) 321:~~521~~ 522-525)

Please replace the paragraph beginning at page 2, line 34 with the following amended paragraph:

Journal of Biological Chemistry, ~~1997~~ 1977, 252(22), 8002-8006 (Non-Patent Document 4) examined the effect of various compounds on cryoprecipitation (solubility of IgM at low temperature), and discloses that cryoprecipitation decreases when sugars are added or salt concentration is increased. However, this disclosure shows that for effective prevention of cryoprecipitation using any sugars or salts, the sugars or salts must be added at high concentrations of approximately 500 mM or higher. When used as a pharmaceutical, it is preferable to achieve such an effect at lower concentrations.

Please replace the paragraph beginning at page 3, line 13 with the following amended paragraph:

Non-Patent Document 2: Nature (1986) 321: ~~521~~ 522-525

Please replace the paragraph beginning at page 3, line 15 with the following amended paragraph:

Non-Patent Document 4: Journal of Biological Chemistry, ~~1997~~ 1977, 252(22), 8002-8006